Tranzyme

Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies.

Tranzyme Pharma is a biopharmaceutical company focused on the discovery, development, and commercialization of mechanism-based therapies. The company currently has programs for gastrointestinal motility disorders and retains worldwide rights for these programs. The company’s product portfolio includes, TZP-101, for the treatment of post-operative ileus and severe gastroparesis; and TZP-301, for the treatment of obesity and metabolic syndrome. Tranzyme Pharma is based in North Carolina, United States.